See more : Shenzhen MinDe Electronics Technology Ltd. (300656.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Black Bird Biotech, Inc. (BBBT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Black Bird Biotech, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Polaris Group (6550.TW) Income Statement Analysis – Financial Results
- Auxico Resources Canada Inc. (AUXIF) Income Statement Analysis – Financial Results
- Rennova Health, Inc. (RNVA) Income Statement Analysis – Financial Results
- Investeringsforeningen IA Invest – Regulær Invest Nordiske Aktier (IAIRIN.CO) Income Statement Analysis – Financial Results
- Umatrin Holding Limited (UMHL) Income Statement Analysis – Financial Results
Black Bird Biotech, Inc. (BBBT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://blackbirdpotentials.com
About Black Bird Biotech, Inc.
Black Bird Biotech Inc. provides various biotech products. It manufactures and distributes MiteXstream, a plant-based biopesticide for the eradication of spider mites. The company also manufactures and sells CBD Oils, gummies and pet treats, CBD-infused personal care products, and hand sanitizer gel and spray products under the Grizzly Creek Naturals brand name. In addition, it grows industrial hemp under the Montana Hemp pilot program. The company was formerly known as Digital Development Partners, Inc. and changed its name to Black Bird Biotech, Inc. in June 2021. Black Bird Biotech, Inc. is based in Flower Mound, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 82.56K | 104.46K | 57.60K | 17.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.12M | 691.60K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 88.82K | 84.87K | 28.25K | 17.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.03M | 653.36K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -6.26K | 19.59K | 29.36K | -31.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 82.89K | 38.24K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -7.58% | 18.75% | 50.97% | -0.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7.42% | 5.53% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 956.60K | 1.36M | 678.00K | 80.31K | 83.54K | 76.23K | 75.74K | 0.00 | 0.00 | 0.00 | 0.00 | 166.05K | 187.40K | 168.72K | 16.28K | 26.64K |
| Selling & Marketing | 234.52K | 5.23K | 1.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 61.24K | 77.38K | 0.00 | 0.00 | 0.00 |
| SG&A | 1.19M | 1.36M | 679.91K | 80.31K | 83.54K | 76.23K | 75.74K | 85.92K | 0.00 | 0.00 | 0.00 | 227.29K | 264.79K | 168.72K | 16.28K | 26.64K |
| Other Expenses | 88.92K | 109.66K | 29.79K | 0.00 | 0.00 | 0.00 | 0.00 | 85.92K | 76.81K | 71.42K | 86.52K | 0.00 | 0.00 | 0.00 | 6.98K | 9.43K |
| Operating Expenses | 1.32M | 1.47M | 709.70K | 80.31K | 83.54K | 76.23K | 75.74K | 85.92K | 76.81K | 71.42K | 86.52K | 227.29K | 264.79K | 168.72K | 23.25K | 36.06K |
| Cost & Expenses | 1.37M | 1.56M | 737.95K | 80.31K | 83.54K | 76.23K | 75.74K | 85.92K | 76.81K | 71.42K | 86.52K | 1.26M | 918.15K | 168.72K | 23.25K | 36.06K |
| Interest Income | 0.00 | 285.33K | 5.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.00 | 782.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 370.59K | 285.33K | 5.87K | 41.66K | 37.57K | 33.78K | 30.53K | 26.55K | 22.71K | 18.57K | 0.00 | 15.77K | 16.05K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 88.92K | 109.66K | 22.22K | 3.29K | 552.00 | 52.52K | 22.82K | 0.00 | 0.00 | 0.00 | 0.00 | 9.00 | 8.03M | 0.00 | 0.00 | 0.00 |
| EBITDA | -1.20M | -1.42M | -684.28K | -146.38K | -83.54K | -76.23K | -75.74K | -85.92K | -76.81K | -71.42K | -86.52K | -144.39K | -225.77K | -168.72K | -23.25K | -36.06K |
| EBITDA Ratio | -1,452.55% | -1,284.22% | -1,180.17% | -451.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -12.93% | -32.64% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.29M | -1.45M | -684.80K | -80.31K | -83.54K | -76.23K | -75.74K | -85.92K | -76.81K | -71.42K | -86.52K | -144.40K | -8.26M | -168.72K | -23.25K | -36.06K |
| Operating Income Ratio | -1,560.42% | -1,389.20% | -1,188.81% | -451.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -12.93% | -1,193.90% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -370.43K | -360.18K | -5.36K | 27.71K | -37.57K | -33.78K | -30.53K | -26.55K | -22.71K | -18.57K | 0.00 | -15.76K | -15.27K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -1.66M | -1.81M | -690.16K | -121.97K | -121.11K | -110.01K | -106.27K | -112.47K | -99.52K | -89.99K | -86.52K | -160.16K | -8.27M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -2,009.09% | -1,734.00% | -1,198.11% | -686.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14.34% | -1,196.11% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 285.33K | 1.41K | 41.66K | -161.14K | -52.52K | -22.82K | 0.00 | 0.00 | 0.00 | 0.00 | -9.00 | -782.00 | 168.72K | 23.25K | 36.06K |
| Net Income | -1.66M | -2.10M | -691.57K | -163.63K | -121.11K | -110.01K | -106.27K | -112.47K | -99.52K | -89.99K | -86.52K | -160.16K | -8.27M | -168.72K | -23.25K | -36.06K |
| Net Income Ratio | -2,009.09% | -2,007.15% | -1,200.56% | -920.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14.34% | -1,196.11% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.10 | -0.01 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.10 | -0.01 | 0.00 | -0.01 |
| Weighted Avg Shares Out | 330.73M | 194.42M | 120.36M | 120.36M | 45.38M | 85.97M | 85.97M | 85.97M | 85.97M | 85.97M | 85.97M | 85.97M | 86.40M | 17.34M | 10.88M | 2.72M |
| Weighted Avg Shares Out (Dil) | 330.73M | 194.42M | 120.36M | 120.36M | 45.38M | 85.97M | 85.97M | 85.97M | 85.97M | 85.97M | 85.97M | 85.97M | 86.40M | 17.34M | 10.88M | 2.72M |
Black Bird Biotech Announces New CEO; Provides Commentary on Refreshed Path
Disruptive Biotech Firm Appoints Public Markets Veteran Nelson Grist as its Chief Executive Officer and Future Member of its Board of Directors
Black Bird Biotech Launches MiteXstream(TM) Online Store for Direct Sales to Commercial and Home Users
FLOWER MOUND, TX / ACCESSWIRE / October 7, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, announced today that it has launched an online store for its game-changing biopesticide, MiteXstreamTM, to facilitate direct sales to...
Black Bird Biotech Retires Three Separate Convertible Notes with Cash Repayments
FLOWER MOUND, TX / ACCESSWIRE / October 5, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, announced today that it has repaid approximately $225,000 in remaining indebtedness under three separate convertible notes with cash payments....
Black Bird Biotech Announces Important Wide-Ranging Field Tests of its Disruptive MiteXstreamTM Biopesticide by A Second International Agri-Chemical Distributor Based in the Middle East
FLOWER MOUND, TX / ACCESSWIRE / September 28, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that an international agri-chemical distributor based in the Middle East is scheduled to begin field testing MiteXstreamTM...
Black Bird Biotech Seeks Approval in All Remaining States, to Open Up Entire US Market, Including the Projected $45 Billion Cannabis Industry, for its Disruptive Plant-Based MiteXstreamTM Biopesticide Sales Efforts
FLOWER MOUND, TX / ACCESSWIRE / September 21, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that, on the heels of its first sales of its game-changing biopesticide, MiteXstreamTM, it is seeking approval...
Black Bird Biotech Announces First Sales of Disruptive Plant-Based MiteXstreamTM Biopesticide, Prepares for Fourth Quarter Marketing Push Within Cannabis Industry
FLOWER MOUND, TX / ACCESSWIRE / September 14, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that it had achieved the first sales of its game-changing biopesticide, MiteXstreamTM, as it accelerates its planned...
Black Bird Biotech to Seek EPA Approval of MiteXstream(TM) Ready-to-Use Formulation
FLOWER MOUND, TX / ACCESSWIRE / July 21, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that it will seek EPA approval of the Ready-to-Use formulation of MiteXstreamTM, as a necessary first step...
Black Bird Biotech Announces MiteXstream Summer Field Testing on Mite-Plagued Vegetable Crops in Israel by International Agri-Chem Company
FLOWER MOUND, TX / ACCESSWIRE / July 19, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that an international agri-chemical company will begin field testing MiteXstream in Israel later this summer, when the...
Source: https://incomestatements.info
Category: Stock Reports